Plot No.367, Abhey Pur, Industrial Area Phase-1, Panchkula, Haryana 134109
Don't miss out on this limited-time offer to join our successful PCD Pharma network. Fill in your details below and our team will get in touch with you to discuss the best franchise opportunities tailored to your needs.
Gemcitabine 200mg Injection
Therapeutic Category
Oncology, Anticancer
Dosage Form
Injection
Packaging Type
Vial
Packaging
200mg
Price
₹1/-
High-resolution images and Product visuals
Product overview and usage information
Detailed information and research documents
GEMTYLE 200 Injection (Gemcitabine 2000 mg) provides a critical, high-volume dosage form of the established antimetabolite chemotherapy agent, Gemcitabine. It is a fundamental component of treatment regimens for several solid tumors, including: Pancreatic Cancer (often first-line), Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, and Metastatic Breast Cancer.
The drug exerts its powerful effect by acting as a deoxycytidine analog, which is metabolized inside cancer cells into active diphosphate and triphosphate forms. These metabolites efficiently inhibit DNA synthesis and repair, leading to apoptotic cell death. The 2000 mg presentation is particularly optimized for institutional and hospital settings that require larger volumes for patient protocols, often involving combination therapies.
The demand for Gemcitabine is inelastic in the oncology sector, making GEMTYLE 200 a strategic, high-turnover product. We offer a specialized PCD Pharma Franchise opportunity with Monopoly Rights for this high-dose injectable. Partnering with us grants you access to institutional marketing materials, competitive tender support, and excellent profit margins in the rapidly expanding anti-cancer injectable market.
May cause headache, muscle pain, nausea, abdominal discomfort, or mild liver enzyme elevation. Rarely, serious muscle problems (myopathy or rhabdomyolysis) may occur.
Primary hypercholesterolemia Mixed dyslipidemia Familial hypercholesterolemia Prevention of cardiovascular disease in high-risk patients
Take under medical supervision, preferably once daily, with or without food. Regular liver function and lipid profile monitoring is advised. Inform your doctor about any muscle pain, weakness, or pre-existing liver/kidney conditions. Avoid excessive alcohol intake.
Store in a cool, dry place below 25°C, protected from light and moisture. Keep out of reach of children.
Composition : Aspirin 75mg + Rosuvastatin 10mg + Clopidogrel 75mg Tablet
Composition : Aspirin 75 mg + Rosuvastatin 20 mg + Clopidogrel 75 mg capsule
Composition : Rosuvastatin 10 mg + Aspirin 75 mg tablet
Composition : Rosuvastatin 5mg + fenofibrate 160 mg tablet
Composition : Rosuvastatin 10 mg + Ezetimibe 10 mg tablet
Composition : Rosuvastatin (5mg) tablet
Composition : Rosuvastatin Calcium IP eq. to Rosuvastatin (as pellets) 20 mg. + Clopidogrel Bisulphate IP eq. to Clopidogrel 75 mg. Excipients q.s.
Composition : Rosuvastatin 20 mg + fenofibrate 160 mg tablet
This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.
Gemcitabine 200mg Injection has strong demand in the oncology and hospital critical-care segment, making it a valuable product for medical distributors, wholesalers, and pharma franchise partners focusing on cancer care, specialty hospitals, and institutional supply portfolios.
Medical distributors and agencies can benefit from consistent demand for management of lung cancer, pancreatic cancer, breast cancer, bladder cancer, ovarian cancer, and other solid tumors under oncologist supervision. Gemcitabine 200mg is an antineoplastic chemotherapy agent that inhibits cancer cell growth and replication Commonly used in hospital-based oncology treatment protocols This strengthens a reliable oncology injectable portfolio.
Yes, Cafoli LifeCare Pvt Ltd offers PCD pharma franchise opportunities for Gemcitabine 200mg Injection with promotional support, monopoly rights, quality packaging, and competitive pricing for distributors and wholesalers.
Wholesalers and medical agencies benefit from strong oncology hospital demand, institutional supply opportunities, specialty physician prescriptions, reliable supply chain support, and good margins in oncology injectables.
Interested distributors, stockists, and wholesalers can contact Cafoli LifeCare Pvt Ltd to discuss pricing, monopoly territory rights, and distribution opportunities.